Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 28-02 / BIG 1-01 (HERA) 

HERA: A randomized, three-arm, multicenter comparison of 1 year and 2 years of herceptin vs. no herceptin in women with HER2 positive primary breast cancer who have completed adjuvant chemotherapy

DESIGN

Design Trial 28-02

Results & Publications


Presentations


Publications

Study Chairs
IBCSG: Dr. Olivia Pagani - Mendrisio, Switzerland
BIG: Dr. Martine J. Piccart - Brussels, Belgium

Trial Coordinators
Holly Shaw


IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg28_hera@fstrf.org


Date of Activation
June 1998

Date of Closure
June 1, 2002

Targeted Accrual
2730 patients

Final Accrual
2890 patients


Results Publications Results & Publications


News

11.07.2014:
New publications are available  

01.06.2014:
New treatment option for young women with hormone‐sensitive breast cancer.

01.06.2014:
ASCO 2014: IBCSG plenary session on TEXT & SOFT trial results.

All News

 
  Print